September 21, 2016

2016-09-21T21:29:20-04:00

https://images.c-span.org/Files/d00/20160921215344001_hd.jpg

The chief executive officer of Mylan testified at a hearing on her company’s price increase on its EpiPen, an anti-anaphylaxis injection medication. Lawmakers from both parties questioned Heather Bresch on the reasons for the price increase, which totaled more than 500 percent over a seven-year period. She defended the price increases, saying the company has boosted EpiPen’s availability to consumers of all means, and to public schools. The deputy director of the Food and Drug administration also appeared at the hearing.

The chief executive officer of Mylan testified at a hearing on her company’s price increase on its EpiPen, an anti-anaphylaxis injection… read more